Weyne, Jonathan
Blauvelt, Andrew
de Bruin-Weller, Marjolein
Prens, Errol
Asbell, Penny
Sierka, Debra
Chen, Zhen
Shumel, Brad
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
https://doi.org/10.1016/s0140-6736(15)00388-8
Patient-Reported Ocular Disorders and Symptoms in Adults with Moderate-to-Severe Atopic Dermatitis: Screening and Baseline Survey Data from a Clinical Trial
https://doi.org/10.1007/s13555-020-00456-x
Dupilumab Maintains Long-Term Disease Control in Adults with Moderate-to-Severe Atopic Dermatitis as Measured by Well-Controlled Weeks: Results From the LIBERTY AD CHRONOS Clinical Trial
https://doi.org/10.1007/s13555-021-00487-y
Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
https://doi.org/10.1007/s13555-021-00657-y
Funding for this research was provided by:
Sanofi
Regeneron Pharmaceuticals
Article History
Received: 5 August 2020
First Online: 12 October 2020